Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMBI

This article was originally published in The Tan Sheet

Executive Summary

Rights to chromium use patents for relieving symptoms of depression, PMS obtained by Chromax marketer under licensing agreement with patent holder Malcolm McLeod, MD, University of North Carolina School of Medicine, firm announces. McLeod has conducted research on chromium use for depression and severe cases of PMS, AMBI notes; additional human studies are underway. AMBI holds numerous patents on chromium picolinate supplement use and has sued several companies for patent infringement (1"The Tan Sheet" May 22, 2000, p. 12)
Advertisement

Related Content

Chromax Chromium Picolinate Patent Infringement Alleged By AMBI
Chromax Chromium Picolinate Patent Infringement Alleged By AMBI

Topics

Advertisement
UsernamePublicRestriction

Register

PS092047

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel